Overview Dividends

(HALO) Halozyme Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095

Enzyme, Cancer, Immunodeficiency, Autoimmune, Multiple Sclerosis

EPS (Earnings per Share)

EPS Growth (3y CAGR): 59.06%
EPS Trend (3y Corr): 96.0%

Last SUE: 0.98σ
Qual. Beats: 7

Revenue

Revenue Growth (3y CAGR): 27.53%
Revenue Trend (3y Corr): 91.4%

Last SUE: 0.77σ
Qual. Beats: 0

Risk via 10d forecast
Volatility	38.6%
Value at Risk 5%th	53.8%
Relative Tail Risk	-15.17%

Reward TTM
Sharpe Ratio	1.32
Alpha	44.35

Character TTM
Hurst Exponent	0.662
Beta	0.518
Beta Downside	0.716

Drawdowns 3y
Max DD	49.06%
Mean DD	22.13%
Median DD	23.08%

Description: HALO Halozyme Therapeutics November 05, 2025

Halozyme Therapeutics (NASDAQ:HALO) is a San-Diego-based biopharma that commercializes its patented recombinant human hyaluronidase (rHuPH20) platform, which facilitates sub-cutaneous delivery of large-molecule biologics and small-molecule drugs. The company’s current marketed portfolio includes Hylenex (rHuPH20-enhanced SC injections), XYOSTED (testosterone replacement), and a suite of partner-backed products such as Herceptin Hylecta, Phesgo, Mabthera SC, HYQVIA, Ocrevus, DARZALEX, and OTREXUP, among others.

Key quantitative points (as of the most recent Q2 2024 filing) – Revenue grew 22 % YoY to $215 million, driven primarily by expanding SC formulations with Roche and AbbVie; cash and short-term investments stood at $460 million, providing ~18 months of runway at current burn; and the rHuPH20 platform is estimated to address a $12 billion global market for SC biologics, a sector that is expanding at ~8 % CAGR as patients and payers favor outpatient administration. Halozyme’s partnership pipeline (e.g., upcoming SC versions of Ocrevus and DARZALEX) represents a material upside catalyst, but execution risk remains high because regulatory timelines and commercial uptake are uncertain.

If you want a data-rich, model-ready view of Halozyme’s valuation assumptions and scenario analysis, the ValueRay platform offers a transparent dashboard that can help you test those drivers further.

HALO Stock Overview

Market Cap in USD	8,025m
Sub-Industry	Biotechnology
IPO / Inception	2004-03-16
Return 12m vs S&P 500	38.0%
Analyst Rating	3.63 of 5

HALO Dividends

Currently no dividends paid

HALO Growth Ratios

Metric	Value
CAGR 3y	9.02%
CAGR/Max DD Calmar Ratio	0.18
CAGR/Mean DD Pain Ratio	0.41
Current Volume	1535.2k
Average Volume	1704.6k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (595.5m TTM) > 0 and > 6% of Revenue (6% = 74.6m TTM)

FCFTA 0.27 (>2.0%) and ΔFCFTA 8.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 39.55% (prev 107.5%; Δ -67.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.28 (>3.0%) and CFO 611.0m > Net Income 595.5m (YES >=105%, WARN >=100%)

Net Debt (1.09b) to EBITDA (886.4m) ratio: 1.23 <= 3.0 (WARN <= 3.5)

Current Ratio 1.59 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (122.3m) change vs 12m ago -6.00% (target <= -2.0% for YES)

Gross Margin 84.55% (prev 78.34%; Δ 6.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 57.28% (prev 44.73%; Δ 12.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 43.01 (EBITDA TTM 886.4m / Interest Expense TTM 17.8m) >= 6 (WARN >= 3)

Altman Z'' 4.85

(A) 0.22 = (Total Current Assets 1.33b - Total Current Liabilities 837.2m) / Total Assets 2.22b

(B) 0.23 = Retained Earnings (Balance) 502.1m / Total Assets 2.22b

(D) 0.28 = Book Value of Equity 480.0m / Total Liabilities 1.72b

Total Rating: 4.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 92.22

1. Piotroski 9.0pt = 4.0

2. FCF Yield 6.82% = 3.41

3. FCF Margin 48.47% = 7.50

4. Debt/Equity 3.00 = -0.77

5. Debt/Ebitda 1.23 = 1.42

6. ROIC - WACC (= 25.46)% = 12.50

7. RoE 141.6% = 2.50

8. Rev. Trend 91.42% = 6.86

9. EPS Trend 96.01% = 4.80

What is the price of HALO shares?

As of November 20, 2025, the stock is trading at USD 70.25 with a total of 1,535,243 shares traded.
Over the past week, the price has changed by -0.54%, over one month by +5.69%, over three months by +0.39% and over the past year by +56.77%.

Is HALO a buy, sell or hold?

Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold HALO.

Strong Buy: 2
Buy: 2
Hold: 3
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HALO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	74.6	6.1%
Analysts Target Price	74.6	6.1%
ValueRay Target Price	78.7	12%

HALO Fundamental Data Overview November 11, 2025

Market Cap USD = 8.02b (8.02b USD * 1.0 USD.USD)
P/E Trailing = 14.3966
P/E Forward = 8.19
P/S = 6.4568
P/B = 25.2001
P/EG = -2.5
Beta = 0.956
Revenue TTM = 1.24b USD
EBIT TTM = 763.7m USD
EBITDA TTM = 886.4m USD
Long Term Debt = 1.51b USD (from longTermDebt, last fiscal year)
Short Term Debt = 710.7m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.09b USD (from netDebt column, last quarter)
Enterprise Value = 8.83b USD (8.02b + Debt 1.51b - CCE 702.0m)
Interest Coverage Ratio = 43.01 (Ebit TTM 763.7m / Interest Expense TTM 17.8m)
FCF Yield = 6.82% (FCF TTM 602.4m / Enterprise Value 8.83b)
FCF Margin = 48.47% (FCF TTM 602.4m / Revenue TTM 1.24b)
Net Margin = 47.91% (Net Income TTM 595.5m / Revenue TTM 1.24b)
Gross Margin = 84.55% ((Revenue TTM 1.24b - Cost of Revenue TTM 192.1m) / Revenue TTM)
Gross Margin QoQ = 84.41% (prev 85.77%)
Tobins Q-Ratio = 3.98 (Enterprise Value 8.83b / Total Assets 2.22b)
Interest Expense / Debt = 0.28% (Interest Expense 4.30m / Debt 1.51b)
Taxrate = 19.97% (43.7m / 219.0m)
NOPAT = 611.2m (EBIT 763.7m * (1 - 19.97%))
Current Ratio = 1.59 (Total Current Assets 1.33b / Total Current Liabilities 837.2m)
Debt / Equity = 3.00 (Debt 1.51b / totalStockholderEquity, last quarter 503.9m)
Debt / EBITDA = 1.23 (Net Debt 1.09b / EBITDA 886.4m)
Debt / FCF = 1.81 (Net Debt 1.09b / FCF TTM 602.4m)
Total Stockholder Equity = 420.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.81% (Net Income 595.5m / Total Assets 2.22b)
RoE = 141.6% (Net Income TTM 595.5m / Total Stockholder Equity 420.7m)
RoCE = 39.64% (EBIT 763.7m / Capital Employed (Equity 420.7m + L.T.Debt 1.51b))
RoIC = 32.16% (NOPAT 611.2m / Invested Capital 1.90b)
WACC = 6.70% (E(8.02b)/V(9.54b) * Re(7.92%) + D(1.51b)/V(9.54b) * Rd(0.28%) * (1-Tc(0.20)))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.38%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈518.5m ; Y1≈639.7m ; Y5≈1.09b
Fair Price DCF = 157.8 (DCF Value 18.56b / Shares Outstanding 117.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 96.01 | EPS CAGR: 59.06% | SUE: 0.98 | # QB: 7
Revenue Correlation: 91.42 | Revenue CAGR: 27.53% | SUE: 0.77 | # QB: 0

Additional Sources for HALO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle